HER2HEART-US: Primary Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy: a Pilot 2x2 Factorial Randomized Controlled Trial
Latest Information Update: 06 May 2025
At a glance
- Drugs Carvedilol (Primary) ; Empagliflozin (Primary)
- Indications Cardiomyopathies
- Focus Therapeutic Use
- Acronyms HER2HEART-US
Most Recent Events
- 18 Apr 2025 Status changed from not yet recruiting to recruiting.
- 05 Mar 2025 New trial record